glp-1 obesity drug news today september 15 2025 Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society Lilly and Novo finalize GLP-1
Description
He has received unrestricted research grants from Celgene/BMS and Novartis
On the other hand, retatrutide is a triple GLP-1 receptors agonist that mimics the effects of GLP-1, GIP, and glucagon
At a poster spotlight session at the 2025 San Antonio Breast Cancer Symposium , researchers presented their recent findings on the effects of GLP-1s on people with breast cancer
Like treatments for high blood pressure or diabetes, they work best when patients receive ongoing care and support
The average follow-up in the study was 3.5 years
The US Food and Drug Administration has also approved certain GLP-1 medications to treat obesity
